skin neoplasms

Clinical and molecular characteristics associated with response to therapeutic PD-1/PD-L1 inhibition in advanced Merkel cell carcinoma
Ivelina Spassova, Selma Ugurel, Linda Kubat, Lisa Zimmer, Patrick Terheyden, Annalena Mohr, Hannah Björn Andtback, Lisa Villabona, Ulrike Leiter, Thomas Eigentler, Carmen Loquai, Jessica C Hassel, Thilo Gambichler, Sebastian Haferkamp, Peter Mohr, Claudia Pfoehler, Lucie Heinzerling, Ralf Gutzmer, Jochen S Utikal, Kai Horny, Hans-Ulrich Schildhaus, Daniel Habermann, Daniel Hoffmann, Dirk Schadendorf, Jürgen Christian Becker

Journal for ImmunoTherapy of Cancer Jan 2022, 10 (1) e003198; DOI: 10.1136/jitc-2021-003198
Ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma: a multicenter study of the prospective skin cancer registry ADOREG
Valerie Glutsch, Patrick Schummer, Hermann Kneitz, Anja Gesierich, Matthias Goebeler, Detlef Klein, Christian Posch, Christoffer Gebhardt, Sebastian Haferkamp, Lisa Zimmer, Jürgen C Becker, Ulrike Leiter, Michael Weichenthal, Dirk Schadendorf, Selma Ugurel, Bastian Schilling

Journal for ImmunoTherapy of Cancer Nov 2022, 10 (11) e005930; DOI: 10.1136/jitc-2022-005930
Leveraging immune memory against measles virus as an antitumor strategy in a preclinical model of aggressive squamous cell carcinoma
Victoria M Leb-Reichl, Melanie Kienzl, Anna Kaufmann, Angelika Stoecklinger, Birgit Tockner, Sophie Kitzmueller, Nadja Zaborsky, Markus Steiner, Gabriele Brachtl, Lisa Trattner, Patrick Kreideweiss, Christian Reinsch, Steffen Panzner, Richard Greil, Dirk Strunk, Johann W Bauer, Iris K Gratz, Christina Guttmann-Gruber, Josefina Piñón Hofbauer

Journal for ImmunoTherapy of Cancer Oct 2021, 9 (10) e002170; DOI: 10.1136/jitc-2020-002170
Real-world clinical outcomes with avelumab in patients with Merkel cell carcinoma treated in the USA: a multicenter chart review study
Shailender Bhatia, Paul Nghiem, S Phani Veeranki, Alejandro Vanegas, Kristina Lachance, Lisa Tachiki, Kevin Chiu, Emily Boller, Murtuza Bharmal

Journal for ImmunoTherapy of Cancer Aug 2022, 10 (8) e004904; DOI: 10.1136/jitc-2022-004904
First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma (JAVELIN Merkel 200): primary and biomarker analyses of a phase II study
Sandra P D'Angelo, Celeste Lebbé, Laurent Mortier, Andrew S Brohl, Nicola Fazio, Jean-Jacques Grob, Natalie Prinzi, Glenn J Hanna, Jessica C Hassel, Felix Kiecker, Sara Georges, Barbara Ellers-Lenz, Parantu Shah, Gülseren Güzel, Paul Nghiem

Journal for ImmunoTherapy of Cancer Jul 2021, 9 (7) e002646; DOI: 10.1136/jitc-2021-002646
Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis
Danny Rischin, Nikhil I Khushalani, Chrysalyne D Schmults, Alexander Guminski, Anne Lynn S Chang, Karl D Lewis, Annette M Lim, Leonel Hernandez-Aya, Brett G M Hughes, Dirk Schadendorf, Axel Hauschild, Alesha A Thai, Elizabeth Stankevich, Jocelyn Booth, Suk-Young Yoo, Siyu Li, Zhen Chen, Emmanuel Okoye, Chieh-I Chen, Vera Mastey, Medha Sasane, Israel Lowy, Matthew G Fury, Michael R Migden

Journal for ImmunoTherapy of Cancer Aug 2021, 9 (8) e002757; DOI: 10.1136/jitc-2021-002757
Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial
Sandra P D'Angelo, Shailender Bhatia, Andrew S Brohl, Omid Hamid, Janice M Mehnert, Patrick Terheyden, Kent C Shih, Isaac Brownell, Celeste Lebbé, Karl D Lewis, Gerald P Linette, Michele Milella, Sara Georges, Parantu Shah, Barbara Ellers-Lenz, Marcis Bajars, Gülseren Güzel, Paul T Nghiem

Journal for ImmunoTherapy of Cancer May 2020, 8 (1) e000674; DOI: 10.1136/jitc-2020-000674
Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma
Paul Nghiem, Shailender Bhatia, Evan J Lipson, William H Sharfman, Ragini R Kudchadkar, Andrew S Brohl, Philip A Friedlander, Adil Daud, Harriet M Kluger, Sunil A Reddy, Brian C Boulmay, Adam Riker, Melissa A Burgess, Brent A Hanks, Thomas Olencki, Kari Kendra, Candice Church, Tomoko Akaike, Nirasha Ramchurren, Michi M Shinohara, Bob Salim, Janis M Taube, Erin Jensen, Mizuho Kalabis, Steven P Fling, Blanca Homet Moreno, Elad Sharon, Martin A Cheever, Suzanne L Topalian

Journal for ImmunoTherapy of Cancer Apr 2021, 9 (4) e002478; DOI: 10.1136/jitc-2021-002478
Glucose-6-phosphate dehydrogenase correlates with tumor immune activity and programmed death ligand-1 expression in Merkel cell carcinoma
Motoki Nakamura, Kotaro Nagase, Maki Yoshimitsu, Tetsuya Magara, Yuka Nojiri, Hiroshi Kato, Tadahiro Kobayashi, Yukiko Teramoto, Masahito Yasuda, Hidefumi Wada, Toshiyuki Ozawa, Yukie Umemori, Dai Ogata, Akimichi Morita

Journal for ImmunoTherapy of Cancer Dec 2020, 8 (2) e001679; DOI: 10.1136/jitc-2020-001679
Clinical, FDG-PET and molecular markers of immune checkpoint inhibitor response in patients with metastatic Merkel cell carcinoma
Alison M Weppler, Andrew Pattison, Prachi Bhave, Paolo De Ieso, Jeanette Raleigh, Athena Hatzimihalis, Anthony J Gill, Shiva Balachander, Jason Callahan, Margaret Chua, George Au-Yeung, Grant A McArthur, Rodney J Hicks, Richard W Tothill, Shahneen Sandhu

Journal for ImmunoTherapy of Cancer Oct 2020, 8 (2) e000700; DOI: 10.1136/jitc-2020-000700

Main menu

skin neoplasms

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

skin neoplasms

Pages